OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/BRAF

Lung Cancer — Non-Small Cell (NSCLC)BRAF Clinical Trials

26 recruiting trials·Updated daily from ClinicalTrials.gov

BRAF V600E mutations occur in 2–3% of NSCLC and are targetable with the FDA-approved dabrafenib plus trametinib combination. Non-V600 BRAF mutations (Class II and III) are less common and respond differently to BRAF/MEK inhibition. Clinical trials explore novel BRAF inhibitors, next-generation combinations, and strategies for non-V600E BRAF-altered NSCLC.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting BRAF Lung Cancer — Non-Small Cell (NSCLC) trials

Ranked by phase and US site count.

See all trials matched to your profile →

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Intergroupe Francophone de Cancerologie Thoracique

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Shouyao Holdings (Beijing) Co. LTD

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Sinocelltech Ltd.

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

ETOP IBCSG Partners Foundation

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Guangdong Provincial People's Hospital

Phase 2/Phase 3

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Cancer Research UK

Additional trials

More BRAF Lung Cancer — Non-Small Cell (NSCLC) trials

Phase 2

NCT06031688Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2267 US sites NCT04302025A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 238 US sites NCT05786924Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPhase 1/Phase 210 US sites NCT07111520A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/Phase 21 US site NCT05589818Pembrolizumab for Advanced NSCLC and PS 2-3Phase 21 US site NCT06364917DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCPhase 21 US site NCT03526835A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPhase 1/Phase 223 US sites NCT06695845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 216 US sites

Phase 1

NCT05538130A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsPhase 157 US sites NCT05355701A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Phase 131 US sites NCT06326411A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsPhase 117 US sites NCT05098210Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerPhase 11 US site

8 international trials (no US sites)

NCT06793813Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)Phase 2 NCT06563999Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 NCT05800340Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLCPhase 2 NCT06929936Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLCPhase 2 NCT06440954Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesPhase 2 NCT06734182Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerPhase 2 NCT06022757Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)Phase 1/Phase 2 NCT07376707A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsPhase 1

Other Lung Cancer — Non-Small Cell (NSCLC) biomarkers

Browse other molecular targets with active Lung Cancer — Non-Small Cell (NSCLC) trials.

EGFR ALK ROS1 PD-L1 (CD274)KRAS MET HER2 (ERBB2)RET NTRK1 NTRK2 NTRK3

← All Lung Cancer — Non-Small Cell (NSCLC) clinical trials